

November 7, 2023

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943 Stock Symbol: JBCHEPHARM

Dear Sir,

Sub.: Disclosure under Regulation 30 of the SEBI (Listing obligations and Disclosure Requirements), Regulations, 2015

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), this is to inform that the Company has received order from Joint Commissioner, Central GST and Central Excise, Vadodara-II Commissionerate.

The relevant information in the format prescribed by SEBI vide its circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is as under:

Name of the authority	Joint Commissioner, Central GST and Central Excise, Vadodara-II Commissionerate
Nature and details of the action(s) taken, initiated or order(s) passed	Demand of ~ Rs 3.61 Cr in respect of Cenvat credit availed by the Company in FY 2013-14.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	6 th November 2023
Details of the violation(s)/contravention(s) committed or alleged to be committed	Wrongful availment of Cenvat credit.



Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible

Company has been advised that it has good case on merits. Company will prefer an appeal before Commissioner (Appeals).

There is no impact on financial, operation or other activities of the Company due to this order.

We request you to take the above on record.

Thanking you,

Yours faithfully, For J.B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis
Vice President – Secretarial
& Company Secretary